Bismuth-Quadruple Therapy as first line eradication regimen of Helicobacter Pylori; experience in a European Union border county Hospital
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S322
DOI: 10.1055/s-0044-1783477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von R. Whitmarsh und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Helicobacter Pylori (HP) has been identified as a Class 1 Carcinogen by the World Health Organisation and should be treated in any positive patients. HP antibiotic-resistance is an increasing problem worldwide with recent Irish data showing Clarithromycin resistance at 25%. European guidelines have suggested an antibiotic should not be used when resistance is>15%. Clarithromycin remains the most prescribed HP eradication regimen in Ireland due to difficulty in sourcing Bismuth despite Bismuth Quadruple Therapy (BQT) being recommended an alternate first line therapy by Irish HSE. Pylera is not available in Ireland. This study was to assessed HP eradication rates with 14-day BQT and identify prohibitive factors associated with its use in Cavan and Monaghan Hospital, Ireland, a peripheral European Union border-county Hospital over an 18-month period.
Methods
Data of HP positive patients treated with BQT was collected from gastroenterology outpatients and endoscopy records including demographic data, HP diagnosis method, method of checking eradication and symptoms. In our centre, Rapid Urease Test (RUT) was carried out using Biohit UFT 300 (Biohit Oyj, Helsinki, Finland). Prohibitive factors of using BQT were identified. All patients were contacted to assess symptoms post therapy and compliance with returning stool samples. Patient engagement was carried out by our Advanced Nurse Practitioner (ANP).
Results
61 HP positive patients were included. The demographics consisted of 52% (n=32) males, mean age 49 (range 17-82). For HP diagnosis; 86% (n=53) had RUT, 12% (n=7) had positive histology, and 2% (n=1) had positive stool antigen (SA). For HP eradication post therapy, 98% (n=60) had negative SA, 2% (n=1) had negative histology. HP eradication with first-line BQT was 90% (n=55). Second-line eradication was 100% (n=6); 1 received Levofloxacin-based-Triple-Therapy and 5 received Levofloxacin-Quadruple-Therapy. Prohibitive factors were only identified early during usage of BQT. This included availability of Bismuth, which was overcome with local and hospital pharmacy engagement, and cost of therapy, which was overcome when changing from Tetracycline to Doxycycline. 100% of patients complied with eradication therapies and returning samples which is due to patient engagement by ANP. All patients had dyspepsia as initial symptom with resolution seen in 92% (n=56) post-eradication.
Conclusions
Our study confirms excellent HP eradication rates (90%) with first-line BQT with 100% eradication achieved with second line therapy in an Irish setting. Prohibitive factors identified were easily overcome with ongoing engagement. Patient engagement by the ANP ensured compliance with therapy and sample return. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Whitmarsh, R., & Ismail, S. (2024). Bismuth-Quadruple Therapy as first line eradication regimen of Helicobacter Pylori; experience in a European Union border county Hospital. Endoscopy, 56(S 02 S 02), S322. https://doi.org/10.1055/s-0044-1783477
Vancouver
Whitmarsh R, Ismail S. Bismuth-Quadruple Therapy as first line eradication regimen of Helicobacter Pylori; experience in a European Union border county Hospital. Endoscopy. 2024;56(S 02 S 02):S322. doi:10.1055/s-0044-1783477
BibTeX
@article{Whitmarsh2024,
author = {Whitmarsh, R. and Ismail, S.},
title = {Bismuth-Quadruple Therapy as first line eradication regimen of Helicobacter Pylori; experience in a European Union border county Hospital},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S322},
doi = {10.1055/s-0044-1783477}
}
EUVIMED